Chen et al. (2007) Reversine increases the plasticity of lineage-committed mammalian cells. Proceeding of the National Academy of Sciences, 104 (25):10482-7.
 d’Alise et al. (2008) Reversine, a novel Aurora kinase inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Molecular Cancer Therapeutics, 7 (5):1140-9.
 Santaguida et al. (2010) Dissecting the role of Mps1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. The Journal of Cell Biology, 190 (1):73-87.
 Libouban et al. (2018) Stable aneuploid tumor cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget, 8 (24):38309-25.
 Kooijman et al. (2022) Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 12:953013.
 Uitdehaag et al. (2016) Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors. Molecular Cancer Therapeutics, 15 (12):3097-109.
 Willemsen-Seegers et al. (2017) Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance. Journal of Molecular Biology, 429:574-86.